Logo of Phnom Penh Post newspaper Phnom Penh Post - Pfizer’s profits in 2021 doubled to $22B on strong Covid-19 jab sales

Pfizer’s profits in 2021 doubled to $22B on strong Covid-19 jab sales

Content image - Phnom Penh Post
Pfizer reported annual profits in 2021 more than doubled to $22 billion on strong sales of Covid-19 vaccines. AFP

Pfizer’s profits in 2021 doubled to $22B on strong Covid-19 jab sales

Pfizer forecast more than $50 billion in 2022 sales for its Covid-19 vaccine and therapeutic on February 8 as the pharmaceutical giant reported a more than doubling of annual profits on strong sales of its inoculation.

Pfizer, whose vaccine developed with German company BioNTech was the first approved in the US to counter the deadly virus, sees slightly lower 2022 revenues for the vaccine compared with the just-finished year, but a big infusion of revenues from Paxlovid, the company’s pill for Covid-19.

CEO Albert Bourla described 2021 as a “watershed year” for Pfizer, adding that the company’s efforts in the pandemic “have fundamentally changed our company forever”.

Still, shares fell on February 8 following the results, which lagged estimates in terms of fourth-quarter revenues.

Besides vaccines, sales were mixed across Pfizer’s other divisions. Revenues dipped for internal medicine and inflammation and immunology, but rose for oncology, hospitals and rare disease.

Analysts have also projected higher 2022 profits compared with the company’s forecasts.

Pfizer reported annual profits of $22 billion, more than double the 2020 level. Annual revenues nearly doubled to $81.3 billion, with $36.8 billion from the Covid-19 vaccine.

The company projected 2022 revenues of between $98 and $102 billion.

The results are the latest to show how the coronavirus has transformed Pfizer, which a year ago had projected just $15 billion in Covid-19 vaccines sales in 2021 and ended up selling more than twice that amount after repeatedly lifting the forecast.

For 2022, Pfizer expects $32 billion in revenue from Covid-19 vaccines and $22 billion in revenues from Paxlovid.

Bourla said the company is currently working on a new vaccine candidate based on the Omicron variant of the novel coronavirus, as well as a new “potential next-generation oral Covid-19 treatment”.

The company expects to produce 120 million treatment courses for Paxlovid, with six million in the first quarter and 30 million the first half of 2022.

Pfizer executives described heavy interest in Paxlovid, with ongoing contract talks with about 100 governments around the world. The treatment has so far been approved in about 40 countries.

Bourla said the sales for Paxlovid “could be way bigger” than current forecasts. The 2022 estimate of $22 billion is based on signed contracts and negotiations where there is essentially an agreement, he said.

However, chief financial officer Frank D’Amelio cautioned that there was “less potential upside” to 2022 estimates for Covid-19 vaccine revenues, compared with 2021 “when the vaccine was newly available and few people had received any doses of the vaccine”.

Morningstar’s Damien Conover estimated that Covid-19-related products will account for $60 billion in revenues in 2022, but fall to close to $5 billion by 2025.

“We expect increased near-term utilisation of Covid vaccines will reduce the demand for these vaccines and treatments over the long term,” Conover said in a note. “We view Pfizer as slightly overvalued, with the market likely extrapolating strong Covid vaccine and treatment sales too far into the future.”

Bourla said the company’s scientists “continue to monitor the Covid-19 virus and believe it is unlikely that it will be fully eradicated in the foreseeable future”.

“That said, we now have the tools – in the forms of vaccines and treatments – that we believe will help enable us to not only better manage the pandemic but also help countries move into the endemic phase,” he said.

Shares fell 2.8 per cent to $51.70.

MOST VIEWED

  • Angkor lifetime pass, special Siem Reap travel offers planned

    The Ministry of Tourism plans to introduce a convenient, single lifetime pass for foreign travellers to visit Angkor Archaeological Park and potentially other areas. The move is designed to stimulate tourism to the culturally rich province of Siem Reap as the start of the “Visit

  • Exclusive interview with Josep Borrell Fontelles, High Representative of the EU

    CAMBODIA is hosting the 55th ASEAN Foreign Ministers’ Meeting (AMM) and Related Meetings this week with top officials from the US, China, and Russia and other countries in the region slated to attend and to meet with face-to-face with their counterparts on the sidelines. In

  • ASEAN Foreign Ministers’ meet commences, Taiwan issue possibly on table

    The 55th ASEAN Foreign Ministers’ Meeting (AMM) and related meetings hosted by Cambodia kicks off in Phnom Penh on August 3, with progress, challenges, and the way forward for the ASEAN Community-building on the table. Issues on Taiwan, sparked by the visit of US House Speaker

  • Pailin longan winery tries to break through to the big time

    Longan aren’t quite as glamorous as some fruits. They don’t have the star-power of mangos or generate the excitement of a pricey seasonal niche fruit like the pungent durian. Unlike bananas or oranges, which are known and loved everywhere, longan remains a decidedly

  • Recap of this year’s ASEAN FM meet and look ahead

    This year’s edition of the ASEAN Foreign Ministers’ Meeting (AMM) hosted by Cambodia comes against the backdrop of heightened global tensions and increasing rivalry between major powers that have been compared to the animosity of the Cold War era. The following is The Post’

  • Siem Reap action plan for tourism in motion

    The action plan for the Siem Reap Tourism Development Master Plan (2022-2023), focusing on six priority destinations, has been implemented to boost tourism and regain pre-Covid tourist numbers in the province. The action plan sets out 17 strategies and 37 implementation activities for: Angkor Archaeological Park, Phnom